Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth J Pienta

Showing results (461-470 of 519) with videos related to

Pageof 52
Sort By:
The Journal of Urology|July 25, 2017
Prostate Specific Membrane Antigen Targeted <sup>18</sup>F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center StudyMichael A Gorin, Steven P Rowe, Hiten D Patel, et al.
Genes, Chromosomes & Cancer|August 5, 2005
Amplification and overexpression of prosaposin in prostate cancerShahriar Koochekpour, Yu-Jun Zhuang, Rameen Beroukhim, et al.
Biorxiv : the Preprint Server for Biology|March 3, 2023
MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progressionJiayu Chen, Qizhi Zheng, Jessica L Hicks, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 22, 2019
Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902Daniel A Hamstra, Stephanie L Pugh, Herbert Lepor, et al.
World Journal of Urology|September 8, 2018
Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatmentC Leigh Moyer, Ryan Phillips, Matthew P Deek, et al.
American Journal of Clinical and Experimental Urology|September 20, 2021
Twelve unanswered questions in cancer inspired by the life and work of Leland Chung: "if this is true, what does it imply"?Melvin Li, Anna Lk Gonye, Kevin Truskowski, et al.
JCI Insight|November 16, 2023
MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progressionJiayu Chen, Qizhi Zheng, Jessica L Hicks, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 20, 2021
Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen-Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or EnzalutamideKatherine A Zukotynski, Urban Emmenegger, Sebastien Hotte, et al.
BMC Cancer|July 1, 2017
A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE)Noura Radwan, Ryan Phillips, Ashley Ross, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 5, 2008
Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibitionSanjeev Shangary, Dongguang Qin, Donna McEachern, et al.
Pageof 52

Showing results (461-470 of 519) with videos related to

Sort By:
Pageof 52
The Journal of Urology|July 25, 2017
Prostate Specific Membrane Antigen Targeted <sup>18</sup>F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center StudyMichael A Gorin, Steven P Rowe, Hiten D Patel, et al.
Genes, Chromosomes & Cancer|August 5, 2005
Amplification and overexpression of prosaposin in prostate cancerShahriar Koochekpour, Yu-Jun Zhuang, Rameen Beroukhim, et al.
Biorxiv : the Preprint Server for Biology|March 3, 2023
MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progressionJiayu Chen, Qizhi Zheng, Jessica L Hicks, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 22, 2019
Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902Daniel A Hamstra, Stephanie L Pugh, Herbert Lepor, et al.
World Journal of Urology|September 8, 2018
Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatmentC Leigh Moyer, Ryan Phillips, Matthew P Deek, et al.
American Journal of Clinical and Experimental Urology|September 20, 2021
Twelve unanswered questions in cancer inspired by the life and work of Leland Chung: "if this is true, what does it imply"?Melvin Li, Anna Lk Gonye, Kevin Truskowski, et al.
JCI Insight|November 16, 2023
MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progressionJiayu Chen, Qizhi Zheng, Jessica L Hicks, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 20, 2021
Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen-Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or EnzalutamideKatherine A Zukotynski, Urban Emmenegger, Sebastien Hotte, et al.
BMC Cancer|July 1, 2017
A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE)Noura Radwan, Ryan Phillips, Ashley Ross, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 5, 2008
Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibitionSanjeev Shangary, Dongguang Qin, Donna McEachern, et al.
Pageof 52